BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it ...

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to ...

Emergent BioSolutions (EBS) announces that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...

An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...

Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has ...

View Emergent BioSolutions Inc. (EBS) current and estimated P/E ratio data provided by Seeking Alpha.

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Kaseya said the mpox vaccine has been well received in countries that have deployed the vaccine, including in the DRC. He ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Emergent BioSolutions. The Motley Fool has a disclosure policy. Making the world smarter, happier ...